A Deep Dive Into The Promising Results Of Biogen"s BAN2401 And Other Alzheimer"s Treatments

Biogen gained billions of dollars in market value on Friday after announcing promising results from a trial of one of its experimental Alzheimer’s disease drugs, marking a rare dose of good news in the daunting field. Cambridge-based Biogen (Nasda.....»»

Biogen Inc (NASDAQ: BIIB) and its Japanese partner Eisai disclosed encouraging results from an 18-month Phase 2 study of its Alzheimer's therapy BAN2401. .....»»

In July, drugmakers Biogen and Eisai announced positive results to its experimental Alzheimer's drug, known as BAN2401. It was the first time in years that the pha.....»»

Shares of Cassava Sciences Inc. more than doubled toward a near 10-year high in very active trading Tuesday, after the company focused on neurodegenerative disease treatments announced upbeat results from a stu.....»»

LA JOLLA, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), an immunology company developing treatments that harness the patient's innate immune s.....»»

Biogen Inc. said Monday it will buy from Pfizer Inc. a potential treatment for behavioral and neurological symptoms, as a potential treatment for Alzheimer's and Parkinson's, for an upfront payment of $75 million and up to $635 million in pote.....»»

Following Biogen Inc's (NASDAQ: BIIB) presentation of detailed top-line results for aducanumab at the Alzheimer's conference, the stock ended Thursday Latest Ratings for BIIB DateFirmAc.....»»

Analyst Yun Zhong looks at two treatments for Alzheimer Disease and other dementias that could beat the odds and be winners in treating these awful afflictions......»»

Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab......»»

Biogen and partner Eisai Co Ltd are ending two late-stage trials testing the experimental Alzheimer's drug aducanumab, marking the latest setback for an industry racing to develop treatments for the memory-robbing disease......»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Shares of Biogen Inc. soared 12% toward a five-month high in premarket trade Friday, after the biotechnology company and Tokyo-based Eisai Co. Ltd. announced positive results from a.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Shares of Biogen Inc (NASDAQ: BIIB) soared higher by more than 13 percent early Friday morning in reaction to the results of an Alzheimer's disease study.  read more.....»»

On Friday's PreMarket Prep trading show, STAT News senior writer Adam Feuerstein weighed in on the results from Biogen Inc (NASDAQ: BIIB) and Eisai's read more.....»»

Biogen (BIIB) stock was soaring today on positive results from a recent Alzheimer's drug trial conducted along with Eisai......»»

Biogen and Japan’s Eisai said they had positive results from a midstage study of an experimental Alzheimer’s drug, though experts said it was too soon to say the drug marks a real advance......»»

First American Trust's CIO tells Reuters' Fred Katayama why he's bullish on Biogen's prospects. The biotech firm's stock surged after its Alzheimer's drug showed positive results in a mid-stage trial......»»

The biotech sector makes a sharp rise in 30 days post the positive data read out from Biogen's mid-stage Alzheimer's trial on BAN2401. We recommend a few industry playe.....»»